No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Gilead Wins FDA Nod for Liver Disease Drug
Gilead Exits J&J Royalty Deal for Liver Drug Ahead of Potential FDA Nod
IPSEN - Buy-back Programme - Art 5 of MAR - Week 30 - 2024
Ipsen Liver Disease Drugs Endorsed in EU
Ipsen S.A. Non-GAAP EPS of €4.78, Revenue of €1.66B; Raises FY24 Outlook
IPSEN - Buy-back Programme - Art 5 of MAR - Week 28 - 2024
No Data